4th Virtual European
Polymer Conference
12-13 June, 2023

Invited lecture:
Biomedical Applications of Thiomers: New Developments, Relevant Clinical Trials and Advanced Products
Prof. Dr. A. Bernkop-Schnürch
more...

7th European Cyclodextrin
Conference
5-8 September, 2023
Budapest, Hungary

Invited lecture:
Thiolated Cyclodextrins: Mimicking the Workhorses of Our Body
Prof. Dr. A. Bernkop-Schnürch
more...

23rd Symposium ADRITELF
11-13 September, 2023
Trieste, Italy

Invited lecture:
Lipid-based Nanocarriers for Oral peptide Drug Delivery: Hype or Hope?
Prof. Dr. A. Bernkop-Schnürch
more...

Preclinical studies

Orientating cytotoxicity studies for formulation

ThioMatrix performes orientating cytotoxicity studies in order to evaluate the influence of auxiliary agents and excipients on the toxicological potential of your drug. These studies include:

• Ciliary beat frequency studies
  
  
• LDH assay
  
  
• MTT assay
  
  
• BrdU test
  
  
• Red blood cell lysis test

Development and validation of quantification methods

For in vivo studies with a new drug it is essential to establish an accurate and validated quantification method in order to be able to determine drug concentrations in compartments such as plasma or cerebrospinal fluid even in the picogram per ml range. ThioMatrix develops and validates such quantification methods and/or can assist you thereby.

In vivo studies

ThioMatrix designs and performs in vivo studies in small and large animals. Based on the results of such studies drug delivery systems can be optimised. ThioMartix is specialized on:

• tolerability studies
  
  
• dose finding studies
  
  
• pharmacokinetic studies
  
  
• biofeedback studies

Preparation of Common Technical Documents (CTDs) / Quality Overall Summaries (QOSs)

ThioMatrix has technical writing expertise and experience in all major therapeutic areas. We can help organize and prepare CTD and QOS in strict accordance with EU/ICH guidelines and regulations. In addition to traditional paper documents, we provide e-submission services.

Clinical studies

Orientating studies in humans

ThioMatrix organizes, designs and coordinates orientating studies in humans. In comparison to phase I-III clinical trials such orientating studies are more cost-effective in order to provide a proof of concept and/or to obtain data on which further improvements of the drug delivery system can be done.

Phase I-IV clinical trials

ThioMatrix works in conjunction with various CROs for clinical trials. ThioMatrix can therefore coordinate and/or assist projects from first orientating in vitro studies, through the resulting design of the delivery system, preclinical and clinical studies to final approval.

A. Bernkop-Schnürch, CSO ThioMatrix, was honored with the PHOENIX Award 2022
more....